A detailed history of Bio Impact Capital LLC transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Bio Impact Capital LLC holds 349,063 shares of MLTX stock, worth $17.9 Million. This represents 2.75% of its overall portfolio holdings.

Number of Shares
349,063
Previous 343,235 1.7%
Holding current value
$17.9 Million
Previous $15.1 Million 16.61%
% of portfolio
2.75%
Previous 2.42%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$40.15 - $55.4 $233,994 - $322,871
5,828 Added 1.7%
349,063 $17.6 Million
Q2 2024

Aug 14, 2024

BUY
$38.43 - $48.6 $1.81 Million - $2.29 Million
47,185 Added 15.94%
343,235 $15.1 Million
Q1 2024

May 15, 2024

BUY
$43.78 - $63.86 $64,531 - $94,129
1,474 Added 0.5%
296,050 $14.9 Million
Q4 2023

Feb 13, 2024

SELL
$36.35 - $63.02 $19,447 - $33,715
-535 Reduced 0.18%
294,576 $17.8 Million
Q2 2023

Aug 14, 2023

BUY
$19.01 - $51.79 $5.61 Million - $15.3 Million
295,111 New
295,111 $15.1 Million

Others Institutions Holding MLTX

About MoonLake Immunotherapeutics


  • Ticker MLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,925,600
  • Market Cap $1.89B
  • Description
  • MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...
More about MLTX
Track This Portfolio

Track Bio Impact Capital LLC Portfolio

Follow Bio Impact Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bio Impact Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bio Impact Capital LLC with notifications on news.